Danaher Corporation $DHR Shares Sold by Lord Abbett & CO. LLC

Key Points

• Lord Abbett & CO. LLC significantly reduced its holdings in Danaher Corporation by 73.9%, now owning 170,466 shares worth approximately $34.95 million.
• Multiple large investors made substantial adjustments to their stakes in Danaher during the first quarter, with Nuveen LLC acquiring a new position valued at around $833.94 million.
• Danaher reported a quarterly earnings per share (EPS) of $1.80, surpassing analysts' estimates and demonstrating a year-over-year revenue increase of 3.4% to $5.94 billion.

Lord Abbett & CO. LLC lessened its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 73.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 170,466 shares of the conglomerate's stock after selling 483,375 shares during the period. Lord Abbett & CO. LLC's holdings in Danaher were worth $34,946,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Fayez Sarofim & Co grew its stake in shares of Danaher by 0.6% during the 4th quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after purchasing an additional 50 shares during the period. Coastal Bridge Advisors LLC boosted its holdings in Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock worth $252,000 after buying an additional 50 shares in the last quarter. MGO One Seven LLC boosted its holdings in Danaher by 1.3% during the fourth quarter. MGO One Seven LLC now owns 4,285 shares of the conglomerate's stock worth $984,000 after buying an additional 53 shares in the last quarter. Hills Bank & Trust Co grew its position in Danaher by 0.3% during the first quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock valued at $3,693,000 after buying an additional 53 shares during the period. Finally, Sageworth Trust Co increased its holdings in Danaher by 2.3% in the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after buying an additional 54 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Danaher Price Performance

NYSE DHR traded down $0.9530 during trading hours on Wednesday, hitting $211.2470. 3,302,498 shares of the company's stock traded hands, compared to its average volume of 4,344,760. The company has a market capitalization of $151.26 billion, a PE ratio of 44.95, a PEG ratio of 2.96 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The firm's 50-day moving average is $200.46 and its 200-day moving average is $199.62.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business's revenue was up 3.4% on a year-over-year basis. During the same period last year, the company posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on DHR. Leerink Partners increased their target price on shares of Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 23rd. Guggenheim reiterated a "buy" rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft dropped their price objective on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Jefferies Financial Group cut their price target on shares of Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a report on Tuesday, April 22nd. Finally, HSBC dropped their target price on shares of Danaher from $270.00 to $240.00 in a research report on Friday, April 25th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $247.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.